WO1998022127A9 - Pretreatment with growth factors to protect against cns damage - Google Patents
Pretreatment with growth factors to protect against cns damageInfo
- Publication number
- WO1998022127A9 WO1998022127A9 PCT/CA1997/000859 CA9700859W WO9822127A9 WO 1998022127 A9 WO1998022127 A9 WO 1998022127A9 CA 9700859 W CA9700859 W CA 9700859W WO 9822127 A9 WO9822127 A9 WO 9822127A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factors
- mammal
- growth factor
- fgf
- cells
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title claims abstract description 110
- 230000002633 protecting Effects 0.000 title claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 210000001178 Neural Stem Cells Anatomy 0.000 claims abstract description 38
- 230000000926 neurological Effects 0.000 claims abstract description 31
- 206010022114 Injury Diseases 0.000 claims abstract description 28
- 210000001519 tissues Anatomy 0.000 claims abstract description 28
- 230000001537 neural Effects 0.000 claims abstract description 26
- 230000032683 aging Effects 0.000 claims abstract description 25
- 230000001681 protective Effects 0.000 claims abstract description 24
- 241000124008 Mammalia Species 0.000 claims abstract description 20
- 210000004027 cells Anatomy 0.000 claims description 61
- 102100010813 EGF Human genes 0.000 claims description 37
- 101700033006 EGF Proteins 0.000 claims description 37
- 210000000130 stem cell Anatomy 0.000 claims description 31
- 210000004556 Brain Anatomy 0.000 claims description 26
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 claims description 18
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 claims description 18
- 230000035755 proliferation Effects 0.000 claims description 15
- 230000002062 proliferating Effects 0.000 claims description 11
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 10
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 108010033760 Amphiregulin Proteins 0.000 claims description 5
- 102000007299 Amphiregulin Human genes 0.000 claims description 5
- 101700082364 FGF2 Proteins 0.000 claims description 5
- 102100008634 FGF2 Human genes 0.000 claims description 5
- 101700038204 TGFA Proteins 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 102000027757 FGF receptors Human genes 0.000 claims description 4
- 108091008101 FGF receptors Proteins 0.000 claims description 4
- 101700064732 FGF1 Proteins 0.000 claims description 4
- 102100007155 FGF1 Human genes 0.000 claims description 4
- 102100014223 TGFA Human genes 0.000 claims description 4
- 230000003466 anti-cipated Effects 0.000 claims description 3
- 102000001301 EGF receptors Human genes 0.000 claims 3
- 108060006698 EGF receptors Proteins 0.000 claims 3
- 101710014509 celF Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 10
- 210000003061 neural cell Anatomy 0.000 abstract description 10
- 230000002588 toxic Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000003319 supportive Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 42
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 34
- 210000002569 neurons Anatomy 0.000 description 23
- 238000001802 infusion Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 230000000302 ischemic Effects 0.000 description 13
- 239000007924 injection Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000003140 Lateral Ventricles Anatomy 0.000 description 10
- 210000001130 Astrocytes Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 210000001320 Hippocampus Anatomy 0.000 description 8
- 206010061255 Ischaemia Diseases 0.000 description 8
- 208000009025 Nervous System Disease Diseases 0.000 description 8
- 206010029305 Neurological disorder Diseases 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 210000004255 neuroglia Anatomy 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000003542 behavioural Effects 0.000 description 7
- 230000003902 lesions Effects 0.000 description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 231100000618 Neurotoxin Toxicity 0.000 description 6
- 206010061536 Parkinson's disease Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002581 neurotoxin Substances 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 206010001897 Alzheimer's disease Diseases 0.000 description 5
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 5
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 5
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 5
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 description 5
- 206010053643 Neurodegenerative disease Diseases 0.000 description 5
- DIVDFFZHCJEHGG-UHFFFAOYSA-N Oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 5
- 230000001058 adult Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000003291 dopaminomimetic Effects 0.000 description 5
- 230000003204 osmotic Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 101710002767 BACOVA_02645 Proteins 0.000 description 4
- 101700014779 GLB1 Proteins 0.000 description 4
- 102000004329 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
- 108090000821 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 201000001971 Huntington's disease Diseases 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 210000004248 Oligodendroglia Anatomy 0.000 description 4
- 229960001412 Pentobarbital Drugs 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 101710019483 ebgA Proteins 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 3
- 210000001168 Carotid Artery, Common Anatomy 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 101710003421 FGF Proteins 0.000 description 3
- 102100012570 GFAP Human genes 0.000 description 3
- 101700069447 GFAP Proteins 0.000 description 3
- 210000001577 Neostriatum Anatomy 0.000 description 3
- 229940053128 Nerve Growth Factor Drugs 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 3
- 108010009063 Proliferating Cell Nuclear Antigen Proteins 0.000 description 3
- 210000004129 Prosencephalon Anatomy 0.000 description 3
- 210000002763 Pyramidal Cells Anatomy 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 108020003835 TX1 Proteins 0.000 description 3
- 231100000765 Toxin Toxicity 0.000 description 3
- 102000031061 Tyrosine 3-monooxygenases Human genes 0.000 description 3
- 108091000118 Tyrosine 3-monooxygenases Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001351 cycling Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 230000000324 neuroprotective Effects 0.000 description 3
- 230000000508 neurotrotrophic Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 108020003112 toxins Proteins 0.000 description 3
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M CHEMBL593252 Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 102100007493 CNTF Human genes 0.000 description 2
- 210000004289 Cerebral Ventricles Anatomy 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000001105 Femoral Artery Anatomy 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N Kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 210000000627 Locus Coeruleus Anatomy 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000003625 Skull Anatomy 0.000 description 2
- 108010086427 Transforming growth factor alpha Proteins 0.000 description 2
- 101710010406 ZBP14 Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000006474 brain ischemia Diseases 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001120 cytoprotect Effects 0.000 description 2
- 230000003412 degenerative Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000002518 glial Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229950006874 kainic acid Drugs 0.000 description 2
- 230000002297 mitogenic Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000003881 protein kinase c inhibitor Substances 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000001177 retroviral Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 101700050638 thi1 Proteins 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 230000001228 trophic Effects 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1H-benzo[f]chromen-5-yl acetate Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 1
- ZHLCHIQFMOCSSC-UHFFFAOYSA-N 3-methyl-8-(2-methylpropyl)-7H-purine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(CC(C)C)N2 ZHLCHIQFMOCSSC-UHFFFAOYSA-N 0.000 description 1
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 Atropine Drugs 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000701922 Bovine parvovirus Species 0.000 description 1
- 102100003470 CHAT Human genes 0.000 description 1
- 101700073865 CHAT Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 210000003037 Cerebral Aqueduct Anatomy 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 206010009802 Coagulopathy Diseases 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- OHCQJHSOBUTRHG-ZYIXGEAZSA-N Coleonol Natural products O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@H](O)CCC1(C)C OHCQJHSOBUTRHG-ZYIXGEAZSA-N 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 102100015137 DBH Human genes 0.000 description 1
- 101700004080 DBH Proteins 0.000 description 1
- 210000001947 Dentate Gyrus Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 210000004002 Dopaminergic cell Anatomy 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 108010002822 EC 2.1.1.28 Proteins 0.000 description 1
- 102100003738 ENO2 Human genes 0.000 description 1
- 101700070897 ENO2 Proteins 0.000 description 1
- 108009000173 Effects of Nitric Oxide Proteins 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 210000002779 Fornix, Brain Anatomy 0.000 description 1
- 210000004055 Fourth Ventricle Anatomy 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 210000001259 Mesencephalon Anatomy 0.000 description 1
- 229940032018 Neurotrophin 3 Drugs 0.000 description 1
- 108090000742 Neurotrophin-3 Proteins 0.000 description 1
- 102000004230 Neurotrophin-3 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- 210000001009 Nucleus accumbens Anatomy 0.000 description 1
- 102100016339 PNMT Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229950008679 Protamine sulfate Drugs 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N Quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 230000036191 S Phase Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010026080 Somatomedins Proteins 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 210000003523 Substantia Nigra Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000000211 Third Ventricle Anatomy 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 230000003492 excitotoxic Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229930002911 forskolin Natural products 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002008 hemorrhagic Effects 0.000 description 1
- 230000000971 hippocampal Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000000185 intracerebroventricular Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000002474 noradrenergic Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001292 preischemic Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Definitions
- This invention relates to methods for protecting neural cells against injury and death, as a result of trauma, neurodegenerative disease processes, toxic insult, malfunction, or aging by providing factors to the central nervous system of a subject.
- Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease,
- Huntington's disease, multiple and amyotrophic lateral sclerosis, stroke, schizophrenia, epilepsy and diabetic peripheral neuropathy are diseases or disorders which affect millions of people. It is the loss of normal neuronal function which produces the behavioral and physical deficits which are characteristic of each of the different neurological disorders.
- the aging process and physical trauma to the central nervous system both result in the loss of neural cells accompanied by the associated behavioral and physical deficits.
- neurological disorders have become an important concern due to the expanding elderly population which is at greatest risk for these disorders.
- U.S. Patent No. 5,519,035, issued on May 21, 1996 provides a method of treating a patient at risk for stroke with protein kinase C inhibitor in order to protect neuronal cells from death as a result of cerebral ischemia.
- Sufficient protein kinase C inhibitor is administered on a daily basis to ensure that, should an ischemic insult occur, the levels of the agent would be high enough to counteract the neurotoxic effects of nitric oxide produced during the ischemic event.
- Parkinson's disease characterized by the loss of dopamine neurons in the nigrostriatal pathway, is a relatively common neurological disorder.
- the dopaminergic neurotoxin, l-methyl-4-phenyl-l,2,3,6-te_rahydropyridine (MPTP) produces parkinsonian symptoms when administered to humans and is frequently used to induce parkinsonigan in animal models of Parkinson's disease.
- Tomac et al. (1995) (Nature 373 pp 335-339) reported that glial cell line derived neurotrophic factor (GDNF) has a protective effect on dopaminergic neurons when the factor is injected into mouse brain 24 hours before administration of MPTP.
- GDNF glial cell line derived neurotrophic factor
- U.S. Patent 5,438,121 issued on August 1, 1995, relating to brain-derived neuro trophic factor (BDNF), disclosed that BDNF may be added to cell cultures 24 hours prior to exposure to the neurotoxins MPP and 6-OHDA to reduce the amount of cellular damage caused by the neurotoxins.
- U.S. Patent 5,554,601 issued on September 10, 1996 disclosed a method of protecting cells in the central nervous system from cell death through the stimulation of the production of neurotrophic growth factors in ovarectomized animals. The method relies on the chronic administration of an estrogen compound having a unique structure which allows it to cross the blood brain barrier in order to stimulate the production of neurotrophic growth factor proteins such as nerve growth factor (NGF) and BDNF.
- NGF nerve growth factor
- the effect of the estrogen compounds was believed to be due to their protective actions against hypoglycemia and excitatory amino acids, and their stimulatory effects on neurotrophic growth factor production in ovarectomized animals. It was noted that the protective effect was not due to a mitogenic effect of the steroid on neural tissue.
- Methods are provided for protecting mammalian neural tissue from trauma or insult or from the manifestations of neurological disease or disorders or the aging process.
- the method comprises administering to a mammal an effective amount of one or more growth factors to induce multipotent neural stem cell proliferation which results in a protective effect on the neural tissue.
- the growth factor treatment can be completed while the neural tissue is still healthy to provided a prolonged protective effect which lasts weeks and even months after cessation of the treatment.
- Growth factors such as ⁇ T, amphireguliii, fibrobiast growth factor, transformmg growth factor alpha, and the like, and combinations thereof can be exogenously administered to the mammal, for example, to one or more CNS ventricles of the mammal.
- the growth factors can be administered by genetically modifying cells of the mammalian neural tissue to produce the growth factors.
- the growth factors are administered at a time prior to the onset of the trauma or the manifestations of the disease or aging process, in amounts sufficient to cause the neural cell population to be protected from progressive cell damage leading to the death of the cells or their malfunction.
- the invention is also directed to the use of a growth factor, or a combination of growth factors in the manufacture of a medicament for the preventative treatment of neurological or neurodegenerative diseases or disorders, neurological trauma, and/or the aging of neural tissue.
- Figs. 1A-1F depict photomicrographs of Nissl stained coronal sections (10 ⁇ m, bregma -3.3 mm) of control (no pretreatment, non-ischemic; 1A, IB) or one week post-ischemic (IC to 2F) rats that received either vehicle (IC and ID) or EGF (IE and IF) i.c.v. infusion t months prior to an ischemic insult.
- CA1 neurons are present in the non-ischemic controls (1A and IB) and in the EGF-pretreated ischemic animals (IE and IF), but are absent in the vehicle-pretreated ischemic
- the present invention provides methods for the protection of neural tissue from the effects of aging, trauma, toxic insult, neurological diseases or disorders.
- Growth factors are administered to the neural tissue, at a time prior to the onset of trauma or the manifestations of neurological disease or aging, to induce multipotent neural stem cells and neural stem cell progeny to proliferate and generate progeny cells that are capable of differentiating into neurons, astrocytes, and oligodendrocytes.
- Astrocytes in particular have been shown to provide a supportive and protective role in the brain. These cells buffer the environment around neurons and secrete factors which enhance the survival and function of the neurons. Normally, astrocyte turnover in the CNS is limited and large scale replacement of dysfunctional astrocytes has not been reported.
- a “multipotent neural stem cell” is an undifferentiated neural cell which is capable of extensive self renewal, i.e., is capable of replacing itself during cell division over an extended period of time, and is capable of generating the major cell types of the tissues in which it is located (i.e. neurons and glia - astrocytes and oligodendrocytes).
- the non-stem cell progeny of a neural stem cell are termed progenitor cells. Methods of proliferating neural stem cells in vitro and in vivo have been previously described (see e.g. WO 93/01275, WO 94/10292, and U.S. Ser. No. 08/486,648).
- neural progenitor cell refers to an undifferentiated cell derived from a neural stem cell, and is not itself a stem cell.
- a distinguishing feature of a progenitor cell is that, unlike a stem cell, it has limited proliferative ability and thus does not exhibit self-maintenance. It is committed to a particular path of differentiation and will, under appropriate conditions, eventually differentiate into either glia (astrocytes or oligodendrocytes) or neurons, and is thus not multipotent.
- precursor cells refers to the progeny of neural stem cells, and thus includes both progenitor cells and daughter neural stem cells.
- ventricle refers to any cavity or passageway within the CNS through which cerebral spinal fluid flows and includes any collapsed portions of the ventricular system. Thus, the term not only encompasses the lateral, third, and fourth ventricles, but also encompasses the central canal, cerebral aqueduct, and other CNS cavities and collapsed CNS cavities.
- growth factor refers to a protein, peptide or other molecule having a growth, proliferative, differentiative, or tropic effect on neural stem cells and/or neural stem cell progeny.
- Growth factors which may be used for inducing proliferation include any factor that allows neural stem cells and precursor cells to proliferate, including any molecule which binds to a receptor on the surface of the neural stem cell to exert a tropic, or growth-inducing effect on the cell, including any protein, amino acid, vitamin, carbohydrate, or other molecule or atom.
- Preferred proliferation-inducing growth factors include EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor
- bFGF or FGF-2 transforming growth factor alpha
- TGF ⁇ transforming growth factor alpha
- a preferred combination of proliferation-inducing growth factors is EGF or TGF ⁇ with FGF-1 or FGF-2.
- neural stem cell progeny that have been induced to proliferate in vivo by administration of growth factors undergo differentiation into cell types that are beneficial to the treated area.
- a likely mechanism is that the neural stem cell progeny respond to extrinsic signals that influence them to differentiate into needed cell types.
- Differentiated progeny of neural stem cells include neurons, astrocytes (type I or type 2) and oligodendrocytes.
- the differentiative pathway of the neural stem cell progeny can be influenced by the addition of exogenous growth factors that increase the numbers of a particular cell type that are generated. Differentiation-influencing growth factors that can be exogenously added are disclosed in WO 94/10292 and U.S. Ser. No. 08/486,648.
- FGF-1 FGF-2
- FGF-2 ciliary neurotrophic factor
- NGF NGF
- BDNF neurotrophin 3
- neurotrophin 4 interleukins
- LIF leukemia inhibitory factor
- cyclic adenosine monophosphate forskolin, high levels of potassium, amphiregulin, TGF- ⁇ , TGF- ⁇ , insulin-like growth factors, dexamethasone (glucocorticoid hormone), isobutyl 3-methylxanthine, somatostatin, growth hormone, retinoic acid, and PDGF, or ligands which bind to the receptors for these growth factors.
- the effects of various growth factors on differentiation can be tested in vitro on cultures of multipotent neural stem cell progeny by using dual-label immunocytochemistry various neuronal- and glial-specific antibodies, the effect of the exogenous growth factors on the differentiation of the cells can be determined.
- Type I astrocytes which are differentiated glial cells, can be identified by their immunoreactivity for GFAP but not A2B5.
- Type II astrocytes which are differentiated glial cells that display a stellate process-bearing morphology, can be identified using immunocytochemistry by their phenotype GFAP(-f-), A2B5(+) phenotype.
- Growth factors can be administered singly or in combination to a patient. They can also be administered in a temporal sequence (e.g. exposure to a first growth factor influences the expression of a second growth factor receptor, Neuron 4:189-201 (1990).
- the growth factors may be prepared in a pharmaceutically-acceptable excipient.
- Administration of the growth factors can be done by any method, including injection cannula or injection to the CNS, peripheral injection, timed- release apparati which can administer substances at the desired site, oral administration, and the like.
- Growth factors can be administered using methods in which the factors may either pass through or by-pass the blood-brain barrier. Methods for allowing factors to pass through the blood-brain barrier include minimizing the size of the factor, or providing hydrophobic factors which may pass through more easily.
- DMSO dimethyl sulfoxide
- i.v. intravenously
- i.p. intraperitoneally
- growth factor growth factor into the CNS.
- Doses of DMSO in mice would be from 2-30% DMSO in a volume of approximately 0.25 ml, administered i.v., preferably 10-15%.
- An intraperitoneal administration of DMSO and growth factor would require from 10-30% DMSO. It would be possible to use Boradeption (Science 217: 166 (1982)) Another possibility would be to bind the growth factor to transferrin to transfer it across the blood brain barrier.
- the fact that the majority of neural stem cells are located in the tissues lining ventricles of mature brains offers several advantages for the modification and manipulation of these cells in vivo. Treatment can be tailored accordingly so that stem cells surrounding ventricles near the desired region would be manipulated or modified in vivo using the methods described herein.
- the ventricular system is found in nearly all brain regions and thus allows easier access to the desired areas. If one wants to modify the stem cells in vivo by exposing them to a composition comprising a growth factor or a viral vector, it is relatively easy to implant a device that administers the composition to the ventricle and thus, to the neural stem cells.
- a cannula attached to an osmotic pump may be used to deliver the composition.
- the composition may be injected directly into the ventricles.
- the neural stem cell progeny can migrate into regions that may be subjected to possible damage as a result of injury, disease, or aging.
- the close proximity of the ventricles to many brain regions would allow for the diffusion of a secreted neurological agent by the stem cells or their progeny to the appropriate region.
- the precursor cells can be genetically modified in vivo by transfection of the cells with growth factor or hormone-expressing vectors, so that the neural cells express various biological agents useful in the prevention of neurological disorders, trauma and the effects of aging.
- Methods for genetically modifying multipotent neural stem cells and their progeny are disclosed in published international application no. WO 94/16718.
- the cells may be modified to express other types of neurological agents such as neurotransmitters.
- the genetic modification is performed either by infection of the cells lining ventricular regions with recombinant retroviruses or transfection using methods known in the art including CaPO 4 transfection, DEAE-dextran transfection, polybrene transfection, by protoplast fusion, electroporation, lipofection, and the like [see Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.]. Any method of genetic modification, now known or later developed can be used. With direct DNA transfection, cells could be modified by particle bombardment, receptor mediated delivery, and cationic liposomes.
- chimeric gene constructs When chimeric gene constructs are used, they generally will contain viral, for example retroviral long terminal repeat (LTR), simian virus 40 (SV40), cytomegalo virus (CMV); or mammalian cell-specific promoters such as those for TH, DBH, phenylethanolamine N-methyltransferase, ChAT, GFAP, NSE, the NF proteins (NF-L, NF-M, NF-H, and the like) that direct the expression of the structural genes encoding the desired protein.
- LTR retroviral long terminal repeat
- SV40 simian virus 40
- CMV cytomegalo virus
- mammalian cell-specific promoters such as those for TH, DBH, phenylethanolamine N-methyltransferase, ChAT, GFAP, NSE, the NF proteins (NF-L, NF-M, NF-H, and the like) that direct the expression of the structural genes encoding the desired protein.
- Any expression vector known in the art can be used to express the growth factor, as long as it has a promoter which is active in the cell, and appropriate termination and polyadenylation signals.
- These expression vectors include recombinant vaccinia virus vectors including pSCll, or vectors derived various viruses such as from Simian Virus 40 (SV40, i.e. pSV2-dhfr, pSV2neo, pko-neo, pSV2gpt, pSVT7 and pBABY), from Rous Sarcoma Virus (RSV, i.e. pRSVneo), from mouse mammary tumor virus (MMTV, i.e.
- Simian Virus 40 i.e. pSV2-dhfr
- pSV2neo pko-neo
- pSV2gpt pSVT7 and pBABY
- RSV Rous Sarcoma Virus
- MMTV
- pMSG adenovirus(pMT2)
- HSV herpes simplex virus
- BPV bovine papillomavirus
- EBV Epstein-Barr Virus
- p205 and pHEBo Epstein-Barr Virus
- a retroviral construct is to be used to genetically modify normally quiescent stem cells, then it is preferable to induce the proliferation of these cells using the methods described herein.
- an osmotic infusion pump could be used to deliver growth factors to the central canal several days prior to infection with the retrovirus. This assures that there will be actively dividing neural stem cells which are susceptible to infection with the retrovirus.
- the deficits in movement, cognition, memory and other behavioral symptoms which normally occur in subjects with neurological disorders caused by disease, trauma or aging or a combination of these factors are reduced as a consequence of preventative administration of a growth factor or growth factors capable of stimulating the proliferation of multipotent neural stem cells and/or their progeny.
- the growth factor pretreatment method achieves a prolonged protective effect, thereby eliminating the need for the exogenously administered growth factor to be present at the time of the trauma, disease, or disorder.
- the term "protective effect" means that the growth factor treatment results in a significantly greater number of normally functioning neural cells than would have otherwise been without the growth factor pre-treatment.
- the growth factors may be administered on an ongoing basis or at regular intervals prior to the manifestations of aging or neurological disorders or disease and from one week to several weeks prior to an anticipated neurological trauma or insult, such as what might occur during brain surgery.
- the term "manifestation” refers to the outward sign of a neurological disease or disorder or the aging process.
- clinical memory loss is an outward sign of Alzheimer's Disease, and can be an outward sign of the aging process.
- certain biological processes that ultimately lead to cell death, injury or dysfunction such as the over- or under-expression of certain gene products, may be early events that begin prior to the onset of outward signs of the aging process, neurological diseases and/or disorders.
- Diagnosis of these biological processes or other precursor events of the aging process, neurological disease and/or disorder followed by a suitable growth factor treatment may lead to the prevention or reduction of the manifestations of the aging process and neurological diseases and disorders.
- genetic screening can be used to diagnose patients who are predisposed to certain neurological disorders, such as Huntington's Disease, prior to the onset of manifestations of the disorder. Patients found to be at risk for a neurological disease or disorder can be treated with growth factors to prevent or reduce the progression of the disease.
- Growth factors are administered (or neural cells are genetically modified to express growth factors) prior to the onset of trauma or the manifestations of aging or disease processes at concentrations that are sufficient to result in neural stem cell proliferation.
- the protective effects that are provided by the growth factor treatment are long-term and usually continue for at least one week after treatment has ceased.
- the protective benefits are often sustained at least two weeks after cessation of treatment, and in many cases, a protective effect is sustained for one, and up to two months, or more.
- growth factors or other neurological agents would be delivered to the ventricles of the forebrain to affect in vivo proliferation of the stem cells.
- growth factors and other neurological agents can be easily administered to the lumbar cistern for circulation throughout the CNS.
- Animal models for various neurological diseases, disorders and injury are used to assess the protective effect of growth factor administration to establish suitable dosages and methods of treatment.
- Behavioral testing is performed to compare the abilities of growth factor treated animals with non-treated control animals. Such behavioral tests include learning and memory tests such as the Morris water maze and radial arm maze.
- the data obtained from accepted mammalian animal models, particularly rodent, canine, and primate models are extrapolated to determine suitable protocols for growth factor treatment of humans.
- administration of from about 100 to about 1000 ng growth factor per kilogram of body weight per hour over a period of from about 1 to 10 days is sufficient to induce multipotent neural stem cell proliferation.
- Example 2 demonstrates that epidermal growth factor (EGF), administered icv at a physiologically effective dose, exerts a cytoprotective effect on hippocampal neurons in vivo, preventing the normal neuronal degenerative response following an ischemic insult. While not wishing to be bound by theory, this response appears to be due to the result of the mitogenic effect of the growth factors, resulting in the production of new neural cells, possibly as a result of the induction of proliferation, migration and/or differentiation of quiescent neural stem and progenitor cells and leading to the production of new glial and/or neuronal cells which secrete substances or alter the environment, providing a long term protective effect on the neurons even after the exogenously administered growth factors are no longer present.
- EGF epidermal growth factor
- a patient scheduled to undergo brain surgery may be pretreated with growth factors to prevent neurological trauma.
- growth factors Prior to surgery, growth factors would be administered to brain regions that may be effected during the surgical procedure. Growth factors are administered at least one week prior to the expected CNS trauma. Preferably, the growth factors would be administered at least two, and more preferably, at least four or more weeks prior to the expected trauma to provide time for the proliferation and differentiation of a beneficial number of new neural stem cell progeny.
- the growth factor pretreatment could be completed several weeks in advance of surgery because the protective effect of growth factor pretreatment is observed for prolonged periods after cessation of the treatment.
- Certain types of professional athletes such as boxers, are also at high risk for neurological trauma, and could be treated with growth factors to achieve a neuroprotective effect. Additionally, patients who are at high risk for stroke can be treated with growth factors to reduce the amount of neurological damage should a stroke occur.
- Example 3 demonstrates that in very old animals, the ability to generate an active constitutively proliferating progenitor cell (CPC) population is impaired.
- CPC progenitor cell
- Neural precursor populations are shown to decline with age, perhaps as a result of a slowing stem cell cycle time. This in turn may lead to degenerative changes in brain morphology, increased susceptibility to ischemic and toxic insults, and increased frequency of cognitive disorders that are often seen in aged animals.
- administration of growth factors such as EGF and FGF to the healthy CNS results in the presence of more healthy, young cells in the aging brain.
- healthy CNS tissue it is meant that the stem cell cycle time and the neural tissue in general are normal for mammals of the same species and age group.
- the treated mammal has at least a 5% increase, and more preferably, a 10% increase, in the number of CPCs relative to the average CPC count for age-matched mammals of the same species.
- the increase in CPC count is sustained for extended time periods, preferably for at least one to two months, and more preferably, for at least four months after cessation of growth factor treatment.
- Example 1 In Vivo Proliferation of Neural Stem Cells of Lateral Ventricle
- a replication incompetent retrovirus containing the ⁇ -galactosidase gene [as described in Walsh and Cepko, Science 241:1342, (1988)] was injected into the forebrain lateral ventricles of CD1 adult male mice (25-30 g from Charles River).
- the injected retrovirus was harvested from the BAG cell line (ATCC CRL-9560) according to the method of Walsh and Cepko (supra). Mice were anesthetized using 65 mg/kg, i.p. sodium pentobarbital.
- Unilateral stereotactic injections of 0.2-1.0 ⁇ l of retrovirus were injected into the lateral ventricle using a 1 ⁇ l Hamilton syringe.
- the coordinates for injection were AP +4.2 mm anterior to lambda, L +_ 0.7 mm, and DV -2.3 mm below dura, with the mouth bar at -2mm below the interaural line.
- an infusion cannulae attached to a 0.5 ⁇ l/hour ALZET osmotic mini-pumps filled with 3.3 - 330 ⁇ g/ml of EGF were surgically implanted into the lateral ventricles at the identical stereotactic coordinates as stated above.
- the infusion cannula kits were obtained from ALZA.
- the infusion cannulae were cut to 2.7 mm below the pedestal.
- the pumps were secured to the mouse skull by use of acrylic cement and a skull screw contralateral and caudal to the injection site.
- the osmotic mini-pump was situated subcutaneously under and behind the armpit of the left front paw and connected to the infusion cannula by the means of polyethylene tubing.
- infusion of EGF resulted in an expansion of the population of ⁇ -gal labeled cells from an average of 20 cells per brain up to an average of 150 cells per brain and the migration of these cells away from the lining of the lateral ventricles.
- Infusion of FGF-2 at 33 ⁇ g/ml resulted in an increase in the number of ⁇ -gal labeled cells, but this increase was not accompanied by any additional migration.
- Infusion of EGF and FGF together resulted in an even greater expansion of the population of ⁇ -gal labeled cells from 20 cells per brain to an average of 350 cells per brain.
- the synergistic increase in ⁇ -galactosidase cell number when EGF and FGF are infused together further reflects the direct association between the relatively quiescent stem cell and the constitutively proliferating progenitor cell.
- This experiment can be modified to infuse growth factors in other CNS ventricles to achieve a similar expansion of cell numbers in other CNS regions.
- Example 2 Growth Factor Infusion Prior to Neurological Insult Epidermal Growth Factor (EGF) (Chiron Corp.) was prepared in 1 mg/ml rat albumin (Calbiochem, Cat. No. 126722) in sterile physiological saline. The EGF preparation was infused into the rostral lateral ventricle (Bregma +0.7 mm) of adult male Wistar rats weighing 250- 350 g via a 30 gauge cannula connected to an osmotic minipump (Alza, Model 2001) at a rate of 1 ⁇ l/hr for 9 days. The EGF was prepared at a concentration so as to provide each animal with 416 ng EGF per kilogram of body weight every hour.
- EGF Neurological Insult Epidermal Growth Factor
- the model used was a combination of rodent models used routinely for transient global ischemia which combines bilateral common carotid artery occlusion with hemorrhagic hypotension (Smith et al. Act. Neurol. Scand 6 . 2:385-401 (1984); Mudrick and Baimbridge, Exp'l Brain Res. £6_:233-247 (1991)).
- This model produced lesions of the neurons in the CAl region (100% of animals) and in the CA2 and CA3 regions (60% of animals) of the hippocampus bilaterally.
- the animals were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and treated with atropine (0.2 mg/kg i.p.) to reduce respiratory secretions.
- a rectal temperature probe connected to a temperature regulated heat pad, was used to maintain the animal body temperature at 35°C.
- the common carotid arteries and the femoral artery were isolated using blunt dissection and a 3-0 silk was looped around each vessel for later access. The femoral artery was then cannulated and heparin (150 units) was administered to prevent clotting.
- the baseline mean arterial pressure was taken ( ⁇ 120/80 mmHg) via a transducer and recorded on a chart recorder.
- the animal was hemorrhaged until mean arterial pressure fell to 30-40 mmHg (removal of approximately 7-10 ml of blood).
- the common carotid arteries were quickly occluded with atraumatic arterial clamps for 20 minutes.
- Mean arterial pressure was maintained at 30-40 mmHg throughout the duration of the ischemia by either further hemorrhage or reinfusion of blood. Blood flow was restored by removal of the arterial clamps, and reinfusion of shed blood.
- Protamine sulfate 1.5 mg/animal was administered via the femoral cannula to deactivate heparin to prevent post-surgical bleeding.
- Mean arterial pressure should return to pre-ischemic levels or slightly higher.
- the animal was given 5 ml of lactated Ringers s.c. and allowed to recover under a warm lamp. The animal was single-housed and monitored closely for the next 48 hours.
- Tissue processed for morphology was defatted in Histoclear (Diamed, Cat. No. HS- 200), rehydrated through a descending series of alcohols, rinsed in distilled water and stained with Thionin (0.5%). Tissue was then dehydrated through a series of alcohols, cleared with Histoclear, and coverslipped with DPX (Aldrich, Cat. No. 31761-1). Thionin stains the Nissl substance within the cytoplasm of nerve cells (Cajal, 1995). The absence of cells with the characteristic pyramidal cell morphology within the cell layer is indicative of a loss of hippocampal pyramidal neurons due to ischemia-induced cell death.
- a one week post ischemia survival time was chosen due to the unique characteristic of delayed neuronal death observed in CAl pyramidal cells in response to transient global ischemia (Shigeno et al. . Neurosci. 11:2914-2919 (1991); Ordy et al. Exp'l Neurol. 119:128-139 (1993)) whereby select CAl pyramidal cells appear unaffected by ischemia for up to 3 days post surgery. In addition, maximal glial reaction has occurred and excitotoxic conditions have subsided by this time point.
- EGF pretreatment icv infusion of EGF for a 9 day period
- EGF-treated animals revealed that the cells of the CAl, CA2 and CA3 displayed excellent morphology throughout the extent of the hippocampus ( Figure 1).
- Example 3 Growth Factor Administration Prior to Onset of Advanced Aging Assessment of precursor cells in rodents of various ages
- the adult subventricular zone consists of at least two populations of dividing cells that can be distinguished by differences in their cell cycle times: a slowly cycling stem cell population and a rapidly cycling, constitutively proliferating progenitor cell (CPC) population.
- CPC constitutively proliferating progenitor cell
- mice of various ages were injected with BrdU (approximately 67 mg/kg) for 4 weeks (3-5 times/day) and left undisturbed for a further 8 weeks.
- This paradigm resulted in labeling of the slowly cycling stem cells of the subventricular zone. Animals were perfused with 4% paraformaldehyde and the brains are removed and cryoprotected. Frozen sections were cut at 30 ⁇ m. BrdU was detected immunocytochemically (rat anti-BrdU, Sera labs, followed by donkey anti-rat CY3 or FITC, Jackson Immunoresearch). Labeled cells throughout the brain were quantified and changes in cell numbers or distribution with age were analyzed. In addition, the distribution of BrdU-immunoreactive, post-mitotic stem cell progeny in the brain was quantified and compared among ages.
- PCNA proliferating cell nuclear antigen
- EGF-treated animals are allowed to age and are given a variety of memory and other behavioral tests and compared with animals of the same age that have not received EGF treatments. Improved performance of EGF-treated animals compared to non-treated animals demonstrates that pretreatment with growth factors can protect against or reduce age-related declines in cognitive function.
- Parkinson's Disease Model Animals receive EGF infusion treatments as described in Example 2 for 6 days (mice) or 9 days (rats). After various time points (1 wk, 2 wk, 1 mo., 2 mos., 4 mos. and 8 mos.) after EGF treatment, animals are lesioned so as to model Parkinson's Disease. In rat models, lesions are made by knife-cuts of the dopaminergic fibers projecting from the midbrain to the striatum or by one injection of 8 ⁇ g of 6-hydroxydopamine directly into the striatum, nucleus accumbens or the substantia nigra.
- mice lesions are made by administration of two injections at 16 hours interval, of 50 mg MPTP/Kg subcutaneously in volume of 0.5 ml of 0.9% saline solution.
- a subset of animals are allowed to survive one to eight days after lesioning and are then sacrificed.
- the numbers of surviving dopaminergic cells are assayed by tyrosine hydroxylase (TH) immunocytochemistry and are compared with control animals that are lesioned prior to sacrifice but which do not receive growth factor treatment.
- TH tyrosine hydroxylase
- mice Female Wistar rats (180-200 g) are used for this model. The animals receive EGF infusion treatments as described in Example 2 for 9 days. After various time points (1 wk, 2 wk, 1 mo., 2 mos., 4 mos. and 8 mos.) after EGF treatment, animals are lesioned so as to model Alzheimer's Disease. A retractable wire knife (Scouten Knife) is used to partially lesion the fimbria-fornix pathway. Animals are killed at various time points after the lesion (from 1 day to 8 weeks), and the numbers of surviving cells are assayed by Nissel staining in the septum. Controls, lesioned and treated animals are compared. A subset of animals is allowed to survive for prolonged periods for behavioral studies and compared with control animals.
Abstract
Methods for protecting neural tissue from the effects of aging, trauma, toxic insult, neurological diseases or disorders comprise administering growth factors to the neural tissue of a mammal at a time prior to the onset of trauma or the manifestations of neurological disease or aging. The growth factors induce multipotent neural stem cells and neural stem cell progeny to proliferate and generate new neural cells which provide supportive and protective roles against the effects of aging, trauma, toxic insult, neurological diseases or disorders.
Description
PRETREATMENT WITH GROWTH FACTORS TO PROTECT AGAINST CNS
DAMAGE
Field of the Invention:
This invention relates to methods for protecting neural cells against injury and death, as a result of trauma, neurodegenerative disease processes, toxic insult, malfunction, or aging by providing factors to the central nervous system of a subject.
Background of the Invention:
Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease,
Huntington's disease, multiple and amyotrophic lateral sclerosis, stroke, schizophrenia, epilepsy and diabetic peripheral neuropathy are diseases or disorders which affect millions of people. It is the loss of normal neuronal function which produces the behavioral and physical deficits which are characteristic of each of the different neurological disorders. In addition to chronic and acute neurodegenerative disorders, the aging process and physical trauma to the central nervous system both result in the loss of neural cells accompanied by the associated behavioral and physical deficits. In recent years neurological disorders have become an important concern due to the expanding elderly population which is at greatest risk for these disorders.
Recently, in vitro and in vivo studies have shown that administration of certain agents prior to the occurrence of a neurological insult are capable of exerting a protective effect, resulting in a decrease in neuronal loss. U.S. Patent No. 5,519,035, issued on May 21, 1996, provides a method of treating a patient at risk
for stroke with protein kinase C inhibitor in order to protect neuronal cells from death as a result of cerebral ischemia. Sufficient protein kinase C inhibitor is administered on a daily basis to ensure that, should an ischemic insult occur, the levels of the agent would be high enough to counteract the neurotoxic effects of nitric oxide produced during the ischemic event.
Parkinson's disease, characterized by the loss of dopamine neurons in the nigrostriatal pathway, is a relatively common neurological disorder. The dopaminergic neurotoxin, l-methyl-4-phenyl-l,2,3,6-te_rahydropyridine (MPTP) produces parkinsonian symptoms when administered to humans and is frequently used to induce parkinsonionism in animal models of Parkinson's disease. Tomac et al. (1995) (Nature 373 pp 335-339) reported that glial cell line derived neurotrophic factor (GDNF) has a protective effect on dopaminergic neurons when the factor is injected into mouse brain 24 hours before administration of MPTP. Similar results were reported for the neuroprotective effects of GDNF on neurons in the locus coeruleus. Grafting of genetically engineered fibroblasts expressing high levels of GDNF into the locus coeruleus, 24 hours before administration of another dopaminergic neurotoxin, 6-hydroxydopamine (6-OHDA), prevented more than 80% of the 6-OHDA-induced degeneration of noradrenergic neurons in that region (Arenas et al, Neurons 25:1465-1473 [1995]). Basic fibroblast growth factor (bFGF or FGF-2) has a protective role for nigrostriatal cells exposed to MPTP or methylpyridiniumion (MPP ) {Park & Mytilineou Brain Res. 599:83-97 [1992]); Chadi et al. Exp. Brain Res. 97 : 145-158 (1993); Otto and Unsicker J. Neurosci. Res. 54:382-393 (1993). Results from in vitro and in vivo studies indicated that FGF-2, administered for a period of up to 4 days before exposure to the neurotoxins and administered for several days after exposure to the toxins significantly decreased the number of dopaminergic neurons damaged by the toxins. Similar results were reported with EGF on cultured cells (Park & Mytilineou, supra). In addition, FGF- 2 has been shown to have neuroprotective effects in the hippocampus. Koketsu et al. (Ann. Neurol. 35 :451-457 [1994]) reported that FGF-2, administered by continuous intracerbroventricular (icv) infusion for 3 days before and 1 day after focal cerebral ischemia reduced the infarct size produced by the ischemic challenge.
They conclude that the protective effect observed was due to direct trophic action of FGF-2 on neurons, via neuronal gene expression that antagonizes "cell death" programs, or due to trophic effects on glial cells and blood vessels. However, no evidence for glial cell proliferation was observed. Liu et al. Brain Res. 626:335- 338 (1993) reported that FGF-2, delivered icv for 2 days prior to, and 5 days after intraperitoneal injections of the seizure-inducing neurotoxin kainic acid did not affect the behavioral responses to the toxin but did prevent neuronal cell loss in the hippocampus. They suggest the protective effect of the growth factor on the neurons is due to FGF-2 prevention of the rise in neuronal intracellular calcium levels which normally occurs in response to kainic acid administration.
U.S. Patent 5,438,121, issued on August 1, 1995, relating to brain-derived neuro trophic factor (BDNF), disclosed that BDNF may be added to cell cultures 24 hours prior to exposure to the neurotoxins MPP and 6-OHDA to reduce the amount of cellular damage caused by the neurotoxins. U.S. Patent 5,554,601, issued on September 10, 1996 disclosed a method of protecting cells in the central nervous system from cell death through the stimulation of the production of neurotrophic growth factors in ovarectomized animals. The method relies on the chronic administration of an estrogen compound having a unique structure which allows it to cross the blood brain barrier in order to stimulate the production of neurotrophic growth factor proteins such as nerve growth factor (NGF) and BDNF. The effect of the estrogen compounds was believed to be due to their protective actions against hypoglycemia and excitatory amino acids, and their stimulatory effects on neurotrophic growth factor production in ovarectomized animals. It was noted that the protective effect was not due to a mitogenic effect of the steroid on neural tissue.
International application no. WO 95/13364 discloses the administration of growth factors to neural tissue in vivo to induce a patient's stem cells to divide to replace cells that have been damaged as a result of disease.
Summary of the Invention
Methods are provided for protecting mammalian neural tissue from trauma or insult or from the manifestations of neurological disease or disorders or the aging process. The method comprises administering to a mammal an effective amount of one or more growth factors to induce multipotent neural stem cell proliferation which results in a protective effect on the neural tissue. The growth factor treatment can be completed while the neural tissue is still healthy to provided a prolonged protective effect which lasts weeks and even months after cessation of the treatment.
Growth factors such as Σ T, amphireguliii, fibrobiast growth factor, transformmg growth factor alpha, and the like, and combinations thereof can be exogenously administered to the mammal, for example, to one or more CNS ventricles of the mammal. Alternatively, the growth factors can be administered by genetically modifying cells of the mammalian neural tissue to produce the growth factors.
The growth factors are administered at a time prior to the onset of the trauma or the manifestations of the disease or aging process, in amounts sufficient to cause the neural cell population to be protected from progressive cell damage leading to the death of the cells or their malfunction.
The invention is also directed to the use of a growth factor, or a combination of growth factors in the manufacture of a medicament for the preventative treatment of neurological or neurodegenerative diseases or disorders, neurological trauma, and/or the aging of neural tissue.
Description of the Figure:
Figs. 1A-1F depict photomicrographs of Nissl stained coronal sections (10 μm, bregma -3.3 mm) of control (no pretreatment, non-ischemic; 1A, IB) or one week post-ischemic (IC to 2F) rats that received either vehicle (IC and ID) or EGF (IE and IF) i.c.v. infusion t months prior to an ischemic insult. CA1 neurons are present in the non-ischemic controls (1A and IB) and in the EGF-pretreated ischemic animals (IE and IF), but are absent in the vehicle-pretreated ischemic
RECTIFIED SHEET (RULE 91)
animals (IC and ID), demonstrating that EGF pretreatment can protect against ischemia-induced cell death in the CA1 region of the hippocampus.
Detailed Description of the Invention:
The present invention provides methods for the protection of neural tissue from the effects of aging, trauma, toxic insult, neurological diseases or disorders. Growth factors are administered to the neural tissue, at a time prior to the onset of trauma or the manifestations of neurological disease or aging, to induce multipotent neural stem cells and neural stem cell progeny to proliferate and generate progeny cells that are capable of differentiating into neurons, astrocytes, and oligodendrocytes. Astrocytes in particular have been shown to provide a supportive and protective role in the brain. These cells buffer the environment around neurons and secrete factors which enhance the survival and function of the neurons. Normally, astrocyte turnover in the CNS is limited and large scale replacement of dysfunctional astrocytes has not been reported.
A "multipotent neural stem cell" is an undifferentiated neural cell which is capable of extensive self renewal, i.e., is capable of replacing itself during cell division over an extended period of time, and is capable of generating the major cell types of the tissues in which it is located (i.e. neurons and glia - astrocytes and oligodendrocytes). The non-stem cell progeny of a neural stem cell are termed progenitor cells. Methods of proliferating neural stem cells in vitro and in vivo have been previously described (see e.g. WO 93/01275, WO 94/10292, and U.S. Ser. No. 08/486,648).
The term "neural progenitor cell", as used herein, refers to an undifferentiated cell derived from a neural stem cell, and is not itself a stem cell. A distinguishing feature of a progenitor cell is that, unlike a stem cell, it has limited proliferative ability and thus does not exhibit self-maintenance. It is committed to a particular path of differentiation and will, under appropriate conditions, eventually differentiate into either glia (astrocytes or oligodendrocytes) or neurons, and is thus not multipotent.
The term "precursor cells", as used herein, refers to the progeny of neural stem cells, and thus includes both progenitor cells and daughter neural stem cells.
The majority of neural stem cells can be found in the tissue lining the CNS ventricles (including the subependyma) of adult mammals. The term "ventricle" refers to any cavity or passageway within the CNS through which cerebral spinal fluid flows and includes any collapsed portions of the ventricular system. Thus, the term not only encompasses the lateral, third, and fourth ventricles, but also encompasses the central canal, cerebral aqueduct, and other CNS cavities and collapsed CNS cavities.
One or more growth factors may be used to induce the proliferation, migration and/ or differentiation of the multipotent neural stem cells/and or their progeny in vivo. As used herein, the term "growth factor" refers to a protein, peptide or other molecule having a growth, proliferative, differentiative, or tropic effect on neural stem cells and/or neural stem cell progeny. Growth factors which may be used for inducing proliferation include any factor that allows neural stem cells and precursor cells to proliferate, including any molecule which binds to a receptor on the surface of the neural stem cell to exert a tropic, or growth-inducing effect on the cell, including any protein, amino acid, vitamin, carbohydrate, or other molecule or atom. Preferred proliferation-inducing growth factors include EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor
(bFGF or FGF-2), transforming growth factor alpha (TGFα), proliferation-inducing ligands which bind to the EGF and FGF receptors, and combinations thereof. A preferred combination of proliferation-inducing growth factors is EGF or TGFα with FGF-1 or FGF-2. To determine whether a particular growth factor will have proliferative effects when administered in vivo, the effects of the growth factor on in vitro neural stem cell proliferation can be tested using methods already known in the art and disclosed in WO 93/01275, WO 94/10292, and U.S. Ser. No. 08/486,648. Growth factors that induce neural stem cell proliferation in vitro have been found to also have proliferative effects in vivo.
Experimental results indicate that neural stem cell progeny that have been induced to proliferate in vivo by administration of growth factors undergo differentiation into cell types that are beneficial to the treated area. A likely mechanism is that the neural stem cell progeny respond to extrinsic signals that influence them to differentiate into needed cell types. Differentiated progeny of neural stem cells include neurons, astrocytes (type I or type 2) and oligodendrocytes. The differentiative pathway of the neural stem cell progeny can be influenced by the addition of exogenous growth factors that increase the numbers of a particular cell type that are generated. Differentiation-influencing growth factors that can be exogenously added are disclosed in WO 94/10292 and U.S. Ser. No. 08/486,648. Among the growth factors and other molecules that can be used to influence the differentiation of precursor cells are FGF-1, FGF-2, ciliary neurotrophic factor (CNTF), NGF, BDNF, neurotrophin 3, neurotrophin 4, interleukins, leukemia inhibitory factor (LIF), cyclic adenosine monophosphate, forskolin, high levels of potassium, amphiregulin, TGF-α, TGF-β, insulin-like growth factors, dexamethasone (glucocorticoid hormone), isobutyl 3-methylxanthine, somatostatin, growth hormone, retinoic acid, and PDGF, or ligands which bind to the receptors for these growth factors.
The effects of various growth factors on differentiation can be tested in vitro on cultures of multipotent neural stem cell progeny by using dual-label immunocytochemistry various neuronal- and glial-specific antibodies, the effect of the exogenous growth factors on the differentiation of the cells can be determined.
Type I astrocytes, which are differentiated glial cells, can be identified by their immunoreactivity for GFAP but not A2B5. Type II astrocytes, which are differentiated glial cells that display a stellate process-bearing morphology, can be identified using immunocytochemistry by their phenotype GFAP(-f-), A2B5(+) phenotype.
Growth factors can be administered singly or in combination to a patient. They can also be administered in a temporal sequence (e.g. exposure to a first growth factor influences the expression of a second growth factor receptor, Neuron 4:189-201
(1990). The growth factors may be prepared in a pharmaceutically-acceptable excipient. Administration of the growth factors can be done by any method, including injection cannula or injection to the CNS, peripheral injection, timed- release apparati which can administer substances at the desired site, oral administration, and the like. Growth factors can be administered using methods in which the factors may either pass through or by-pass the blood-brain barrier. Methods for allowing factors to pass through the blood-brain barrier include minimizing the size of the factor, or providing hydrophobic factors which may pass through more easily. For example, dimethyl sulfoxide (DMSO) or the like can be administered to reversibly open the blood-brain barrier to allow the passage of intravenously (i.v.) intraperitoneally (i.p.), or orally administered growth factor into the CNS. Doses of DMSO in mice would be from 2-30% DMSO in a volume of approximately 0.25 ml, administered i.v., preferably 10-15%. An intraperitoneal administration of DMSO and growth factor would require from 10-30% DMSO. It would be possible to use Boradeption (Science 217: 166 (1982)) Another possibility would be to bind the growth factor to transferrin to transfer it across the blood brain barrier.
It is presently preferred to administer growth factors directly to one or more ventricles of the CNS. The fact that the majority of neural stem cells are located in the tissues lining ventricles of mature brains offers several advantages for the modification and manipulation of these cells in vivo. Treatment can be tailored accordingly so that stem cells surrounding ventricles near the desired region would be manipulated or modified in vivo using the methods described herein. The ventricular system is found in nearly all brain regions and thus allows easier access to the desired areas. If one wants to modify the stem cells in vivo by exposing them to a composition comprising a growth factor or a viral vector, it is relatively easy to implant a device that administers the composition to the ventricle and thus, to the neural stem cells. For example, a cannula attached to an osmotic pump may be used to deliver the composition. Alternatively, the composition may be injected directly into the ventricles. The neural stem cell progeny can migrate into regions that may be subjected to possible damage as a result of injury, disease, or aging.
Furthermore, the close proximity of the ventricles to many brain regions would allow for the diffusion of a secreted neurological agent by the stem cells or their progeny to the appropriate region.
In addition, or as an alternative to exogenously administering growth factors to precursor cells, the precursor cells can be genetically modified in vivo by transfection of the cells with growth factor or hormone-expressing vectors, so that the neural cells express various biological agents useful in the prevention of neurological disorders, trauma and the effects of aging. Methods for genetically modifying multipotent neural stem cells and their progeny are disclosed in published international application no. WO 94/16718. In addition to genetic modification of the cells to express growth factors, the cells may be modified to express other types of neurological agents such as neurotransmitters.
Preferably, the genetic modification is performed either by infection of the cells lining ventricular regions with recombinant retroviruses or transfection using methods known in the art including CaPO4 transfection, DEAE-dextran transfection, polybrene transfection, by protoplast fusion, electroporation, lipofection, and the like [see Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.]. Any method of genetic modification, now known or later developed can be used. With direct DNA transfection, cells could be modified by particle bombardment, receptor mediated delivery, and cationic liposomes. When chimeric gene constructs are used, they generally will contain viral, for example retroviral long terminal repeat (LTR), simian virus 40 (SV40), cytomegalo virus (CMV); or mammalian cell-specific promoters such as those for TH, DBH, phenylethanolamine N-methyltransferase, ChAT, GFAP, NSE, the NF proteins (NF-L, NF-M, NF-H, and the like) that direct the expression of the structural genes encoding the desired protein.
Any expression vector known in the art can be used to express the growth factor, as long as it has a promoter which is active in the cell, and appropriate termination and polyadenylation signals. These expression vectors include recombinant vaccinia
virus vectors including pSCll, or vectors derived various viruses such as from Simian Virus 40 (SV40, i.e. pSV2-dhfr, pSV2neo, pko-neo, pSV2gpt, pSVT7 and pBABY), from Rous Sarcoma Virus (RSV, i.e. pRSVneo), from mouse mammary tumor virus (MMTV, i.e. pMSG), from adenovirus(pMT2), from herpes simplex virus (HSV, i.e. pTK2 and pHyg), from bovine papillomavirus (BPV, i.e. pdBPV and pBV-lMTHA), from Epstein-Barr Virus (EBV, i.e. p205 and pHEBo) or any other eukaryotic expression vector known in the art. If a retroviral construct is to be used to genetically modify normally quiescent stem cells, then it is preferable to induce the proliferation of these cells using the methods described herein. For example, an osmotic infusion pump could be used to deliver growth factors to the central canal several days prior to infection with the retrovirus. This assures that there will be actively dividing neural stem cells which are susceptible to infection with the retrovirus.
According to this invention, the deficits in movement, cognition, memory and other behavioral symptoms which normally occur in subjects with neurological disorders caused by disease, trauma or aging or a combination of these factors are reduced as a consequence of preventative administration of a growth factor or growth factors capable of stimulating the proliferation of multipotent neural stem cells and/or their progeny. The growth factor pretreatment method achieves a prolonged protective effect, thereby eliminating the need for the exogenously administered growth factor to be present at the time of the trauma, disease, or disorder. The term "protective effect" means that the growth factor treatment results in a significantly greater number of normally functioning neural cells than would have otherwise been without the growth factor pre-treatment. The growth factors may be administered on an ongoing basis or at regular intervals prior to the manifestations of aging or neurological disorders or disease and from one week to several weeks prior to an anticipated neurological trauma or insult, such as what might occur during brain surgery. As used herein, the term "manifestation" refers to the outward sign of a neurological disease or disorder or the aging process. For example, clinical memory loss is an outward sign of Alzheimer's Disease, and can be an outward sign of the aging process. In contrast, certain biological processes that ultimately lead to
cell death, injury or dysfunction, such as the over- or under-expression of certain gene products, may be early events that begin prior to the onset of outward signs of the aging process, neurological diseases and/or disorders. Diagnosis of these biological processes or other precursor events of the aging process, neurological disease and/or disorder followed by a suitable growth factor treatment may lead to the prevention or reduction of the manifestations of the aging process and neurological diseases and disorders. For example, genetic screening can be used to diagnose patients who are predisposed to certain neurological disorders, such as Huntington's Disease, prior to the onset of manifestations of the disorder. Patients found to be at risk for a neurological disease or disorder can be treated with growth factors to prevent or reduce the progression of the disease.
Growth factors are administered (or neural cells are genetically modified to express growth factors) prior to the onset of trauma or the manifestations of aging or disease processes at concentrations that are sufficient to result in neural stem cell proliferation. The protective effects that are provided by the growth factor treatment are long-term and usually continue for at least one week after treatment has ceased. The protective benefits are often sustained at least two weeks after cessation of treatment, and in many cases, a protective effect is sustained for one, and up to two months, or more.
For the prevention or reduction of the manifestations of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, and other neurological disorders affecting primarily the forebrain, growth factors or other neurological agents would be delivered to the ventricles of the forebrain to affect in vivo proliferation of the stem cells. Alternatively, growth factors and other neurological agents can be easily administered to the lumbar cistern for circulation throughout the CNS. Animal models for various neurological diseases, disorders and injury are used to assess the protective effect of growth factor administration to establish suitable dosages and methods of treatment. Behavioral testing is performed to compare the abilities of growth factor treated animals with non-treated control animals. Such behavioral tests include learning and memory tests such as the Morris water maze and radial
arm maze. The data obtained from accepted mammalian animal models, particularly rodent, canine, and primate models are extrapolated to determine suitable protocols for growth factor treatment of humans. Generally, administration of from about 100 to about 1000 ng growth factor per kilogram of body weight per hour over a period of from about 1 to 10 days is sufficient to induce multipotent neural stem cell proliferation.
Example 2 below demonstrates that epidermal growth factor (EGF), administered icv at a physiologically effective dose, exerts a cytoprotective effect on hippocampal neurons in vivo, preventing the normal neuronal degenerative response following an ischemic insult. While not wishing to be bound by theory, this response appears to be due to the result of the mitogenic effect of the growth factors, resulting in the production of new neural cells, possibly as a result of the induction of proliferation, migration and/or differentiation of quiescent neural stem and progenitor cells and leading to the production of new glial and/or neuronal cells which secrete substances or alter the environment, providing a long term protective effect on the neurons even after the exogenously administered growth factors are no longer present. It is expected that administration of large doses of tritiated thymidine or other anti- mitotic agents at the time of growth factor infusion would block the proliferation of the neural cells, and hence block the protective effect that is observed after ischemic insult. This would indicate that the protective effect observed after growth factor treatment results from the addition of new cells to the area.
The discovery that treatment with growth factors provides a cytoprotective effect can be used advantageously to reduce the chances of or lessen the severity of an expected CNS trauma. For example, a patient scheduled to undergo brain surgery may be pretreated with growth factors to prevent neurological trauma. Prior to surgery, growth factors would be administered to brain regions that may be effected during the surgical procedure. Growth factors are administered at least one week prior to the expected CNS trauma. Preferably, the growth factors would be administered at least two, and more preferably, at least four or more weeks prior to the expected trauma to provide time for the proliferation and differentiation of a
beneficial number of new neural stem cell progeny. If desired, the growth factor pretreatment could be completed several weeks in advance of surgery because the protective effect of growth factor pretreatment is observed for prolonged periods after cessation of the treatment. Certain types of professional athletes, such as boxers, are also at high risk for neurological trauma, and could be treated with growth factors to achieve a neuroprotective effect. Additionally, patients who are at high risk for stroke can be treated with growth factors to reduce the amount of neurological damage should a stroke occur.
Example 3 below demonstrates that in very old animals, the ability to generate an active constitutively proliferating progenitor cell (CPC) population is impaired.
Neural precursor populations are shown to decline with age, perhaps as a result of a slowing stem cell cycle time. This in turn may lead to degenerative changes in brain morphology, increased susceptibility to ischemic and toxic insults, and increased frequency of cognitive disorders that are often seen in aged animals. As shown in Example 3, administration of growth factors such as EGF and FGF to the healthy CNS results in the presence of more healthy, young cells in the aging brain. By the phrase "healthy CNS tissue", it is meant that the stem cell cycle time and the neural tissue in general are normal for mammals of the same species and age group. Preferably, at least two weeks after the growth factor treatment, the treated mammal has at least a 5% increase, and more preferably, a 10% increase, in the number of CPCs relative to the average CPC count for age-matched mammals of the same species. The increase in CPC count is sustained for extended time periods, preferably for at least one to two months, and more preferably, for at least four months after cessation of growth factor treatment.
Example 1: In Vivo Proliferation of Neural Stem Cells of Lateral Ventricle
A replication incompetent retrovirus containing the β-galactosidase gene [as described in Walsh and Cepko, Science 241:1342, (1988)] was injected into the forebrain lateral ventricles of CD1 adult male mice (25-30 g from Charles River). The injected retrovirus was harvested from the BAG cell line (ATCC CRL-9560) according to the method of Walsh and Cepko (supra). Mice were anesthetized using
65 mg/kg, i.p. sodium pentobarbital. Unilateral stereotactic injections of 0.2-1.0 μl of retrovirus were injected into the lateral ventricle using a 1 μl Hamilton syringe. The coordinates for injection were AP +4.2 mm anterior to lambda, L +_ 0.7 mm, and DV -2.3 mm below dura, with the mouth bar at -2mm below the interaural line.
One day, or six days following the retrovirus injection, an infusion cannulae attached to a 0.5 μl/hour ALZET osmotic mini-pumps filled with 3.3 - 330 μg/ml of EGF were surgically implanted into the lateral ventricles at the identical stereotactic coordinates as stated above. The infusion cannula kits were obtained from ALZA. The infusion cannulae were cut to 2.7 mm below the pedestal. The pumps were secured to the mouse skull by use of acrylic cement and a skull screw contralateral and caudal to the injection site. The osmotic mini-pump was situated subcutaneously under and behind the armpit of the left front paw and connected to the infusion cannula by the means of polyethylene tubing.
Six days following initiation of EGF infusion the animals were sacrificed with an overdose of sodium pentobarbital. Mice were transcardially perfused with 2% buffered paraformaldehyde, and the brains were excised and post fixed overnight with 20% sucrose in 2% buffered paraformaldehyde. Coronal slices were prepared with -20 Celsius cryostat sectioning at 30 μm. Slices were developed for β-gal histochemistry as per Morshead and Van der Kooy (supra).
Under these conditions, regardless of the day post retrovirus injection, infusion of EGF resulted in an expansion of the population of β-gal labeled cells from an average of 20 cells per brain up to an average of 150 cells per brain and the migration of these cells away from the lining of the lateral ventricles. Infusion of FGF-2 at 33 μg/ml resulted in an increase in the number of β-gal labeled cells, but this increase was not accompanied by any additional migration. Infusion of EGF and FGF together resulted in an even greater expansion of the population of β-gal labeled cells from 20 cells per brain to an average of 350 cells per brain. The synergistic increase in β-galactosidase cell number when EGF and FGF are infused together further reflects the direct association between the relatively quiescent stem
cell and the constitutively proliferating progenitor cell.
This experiment can be modified to infuse growth factors in other CNS ventricles to achieve a similar expansion of cell numbers in other CNS regions.
Example 2: Growth Factor Infusion Prior to Neurological Insult Epidermal Growth Factor (EGF) (Chiron Corp.) was prepared in 1 mg/ml rat albumin (Calbiochem, Cat. No. 126722) in sterile physiological saline. The EGF preparation was infused into the rostral lateral ventricle (Bregma +0.7 mm) of adult male Wistar rats weighing 250- 350 g via a 30 gauge cannula connected to an osmotic minipump (Alza, Model 2001) at a rate of 1 μl/hr for 9 days. The EGF was prepared at a concentration so as to provide each animal with 416 ng EGF per kilogram of body weight every hour.
Precursor Cell Labeling
Animals received BrdU (50 mg/kg) i.p. 3 times per day for the last 3 days of growth factor infusion.
ischemia Lesions
The model used was a combination of rodent models used routinely for transient global ischemia which combines bilateral common carotid artery occlusion with hemorrhagic hypotension (Smith et al. Act. Neurol. Scand 6.2:385-401 (1984); Mudrick and Baimbridge, Exp'l Brain Res. £6_:233-247 (1991)). This model produced lesions of the neurons in the CAl region (100% of animals) and in the CA2 and CA3 regions (60% of animals) of the hippocampus bilaterally. Two months after treatment with EGF, the animals were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and treated with atropine (0.2 mg/kg i.p.) to reduce respiratory secretions. A rectal temperature probe, connected to a temperature regulated heat pad, was used to maintain the animal body temperature at 35°C. The common carotid arteries and the femoral artery were isolated using blunt dissection and a 3-0 silk was looped around each vessel for later access. The femoral artery was then cannulated and heparin (150 units) was administered to prevent clotting.
The baseline mean arterial pressure was taken ( ~ 120/80 mmHg) via a transducer and recorded on a chart recorder. The animal was hemorrhaged until mean arterial pressure fell to 30-40 mmHg (removal of approximately 7-10 ml of blood). The common carotid arteries were quickly occluded with atraumatic arterial clamps for 20 minutes. Mean arterial pressure was maintained at 30-40 mmHg throughout the duration of the ischemia by either further hemorrhage or reinfusion of blood. Blood flow was restored by removal of the arterial clamps, and reinfusion of shed blood. Protamine sulfate (1.5 mg/animal) was administered via the femoral cannula to deactivate heparin to prevent post-surgical bleeding. Mean arterial pressure should return to pre-ischemic levels or slightly higher. The animal was given 5 ml of lactated Ringers s.c. and allowed to recover under a warm lamp. The animal was single-housed and monitored closely for the next 48 hours.
Tissue Preparation
Animals were allowed to survive 1 week after the ischemic insult prior to tissue preparation. The animals were deeply anesthetized with 65 mg/kg sodium pentobarbital and transcardially perfused with ice cold saline ( ~ 350 ml) followed by ice cold 4% paraformaldehyde (PFA) in 0.1M phosphate buffer at pH 7.4 ( — 500ml). Brains were removed and post fixed in 4% PFA overnight at 4°C. The brains were then cryoprotected through serial overnight incubations in 10% to 30% sucrose at 4°C and then incubated for 2-24 hours in 2: 1 30% sucrose.OCT. The brains were then frozen on dry ice and lOμm serial sections were cut on a cryostat.
Histological Evaluation of Neuronal Cell Death
Tissue processed for morphology was defatted in Histoclear (Diamed, Cat. No. HS- 200), rehydrated through a descending series of alcohols, rinsed in distilled water and stained with Thionin (0.5%). Tissue was then dehydrated through a series of alcohols, cleared with Histoclear, and coverslipped with DPX (Aldrich, Cat. No. 31761-1). Thionin stains the Nissl substance within the cytoplasm of nerve cells (Cajal, 1995). The absence of cells with the characteristic pyramidal cell morphology within the cell layer is indicative of a loss of hippocampal pyramidal neurons due to ischemia-induced cell death. A one week post ischemia survival time
was chosen due to the unique characteristic of delayed neuronal death observed in CAl pyramidal cells in response to transient global ischemia (Shigeno et al. . Neurosci. 11:2914-2919 (1991); Ordy et al. Exp'l Neurol. 119:128-139 (1993)) whereby select CAl pyramidal cells appear unaffected by ischemia for up to 3 days post surgery. In addition, maximal glial reaction has occurred and excitotoxic conditions have subsided by this time point.
Results
EGF pretreatment (icv infusion of EGF for a 9 day period) given 8 weeks prior to an ischemic insult produced complete protection in 3 of 7 animals from ischemia- induced neuronal cell death in the CAl region. Nissl stain of EGF-treated animals revealed that the cells of the CAl, CA2 and CA3 displayed excellent morphology throughout the extent of the hippocampus (Figure 1). In addition, there was an increased number of glial cells observed within the hippocampus. BrdU labeling was observed within the hippocampus.
Example 3: Growth Factor Administration Prior to Onset of Advanced Aging Assessment of precursor cells in rodents of various ages
The adult subventricular zone (SVZ) consists of at least two populations of dividing cells that can be distinguished by differences in their cell cycle times: a slowly cycling stem cell population and a rapidly cycling, constitutively proliferating progenitor cell (CPC) population. The purpose of this study was to quantify the numbers and distribution of these cell types with age in the mouse and rat and the impact of growth factor infusion on cell numbers.
Mice of various ages (between 2 and 18 months) were injected with BrdU (approximately 67 mg/kg) for 4 weeks (3-5 times/day) and left undisturbed for a further 8 weeks. This paradigm resulted in labeling of the slowly cycling stem cells of the subventricular zone. Animals were perfused with 4% paraformaldehyde and the brains are removed and cryoprotected. Frozen sections were cut at 30 μm. BrdU was detected immunocytochemically (rat anti-BrdU, Sera labs, followed by donkey anti-rat CY3 or FITC, Jackson Immunoresearch). Labeled cells throughout
the brain were quantified and changes in cell numbers or distribution with age were analyzed. In addition, the distribution of BrdU-immunoreactive, post-mitotic stem cell progeny in the brain was quantified and compared among ages.
The same tissue was double-labeled with antibodies to proliferating cell nuclear antigen (PCNA), which is upregulated around the S phase of the cell cycle. Preliminary results indicate that it marks the constitutively proliferating cell population. The number and distribution of PCNA-IR cells were quantified and compared among ages.
Results The number of mitotically active stem cells (BrdU-IR) declined with age, particularly at stem cell "pockets" where there are higher concentrations of stem cells. At the rostral stem cell pocket (bregma 0.7), counts for the 7 month old group and the 13 month old animal were 65% and 53% of the 2 month values, respectively. Similarly, at the caudal stem cell pocket (bregma -4.3), counts for the 7 month and 13 month groups were 53% and 38% of the 2 month values, respectively.
The CPC population (PCNA-IR) also declined with age. The ages of the animals at the time of sacrifice for CPC analysis were 5, 10, and 16 months. To avoid confusion when comparing data, the age at which the stem cell labeling began (i.e. 2, 7 and 13 months) is used to identify the subset of animals referred to (rather than the age at sacrifice). At bregma 0.7, a previously identified CPC peak, counts for the 7 month group were only 62% of the 2 month values, while the 13 month animal contained only 30% of the 2 month counts. This data contradicts that of Kuhn et al. J. Neuro Sci 1^2027-2033 (1996), who found no change in the number of BrdU-IR cells with age in a restricted area of the rat lateral ventricle when analyzed 1 day after BrdU injection.
The number of BrdU-IR cells in the dentate gyrus of the hippocampus also declined with age.
Effect of growth factors on the aging process of rodents
EGF was infused into the lateral ventricles of two month old adult CD1 mice (n=3), using the procedure described in Example 2 for a period of 6 days. Control mice (n=3) were infused with vehicle. The animals were sacrificed four months later. The number of PCNA-IR cells around the lateral ventricle was measured, using the procedures described above, in 10 μm sections from the following bregmas: 2.7, 2.2, 1.7, 1.2, 0.7, 0.2, -0.3, -0.8. These bregma correspond to the peak cell distributions of CPCs and are the sites where significant loss of PCNA-IR cells with age are seen. Two of the three animals that received EGF treatment had significantly higher PCNA counts (approx. 30% higher) than vehicle controls demonstrating that the EGF has a protective effect on the CPCs in aging animals.
In further studies, EGF-treated animals are allowed to age and are given a variety of memory and other behavioral tests and compared with animals of the same age that have not received EGF treatments. Improved performance of EGF-treated animals compared to non-treated animals demonstrates that pretreatment with growth factors can protect against or reduce age-related declines in cognitive function.
Example 4: Growth Factor Administration Prior to Onset of Neurological
Disease
Parkinson's Disease Model Animals receive EGF infusion treatments as described in Example 2 for 6 days (mice) or 9 days (rats). After various time points (1 wk, 2 wk, 1 mo., 2 mos., 4 mos. and 8 mos.) after EGF treatment, animals are lesioned so as to model Parkinson's Disease. In rat models, lesions are made by knife-cuts of the dopaminergic fibers projecting from the midbrain to the striatum or by one injection of 8 μg of 6-hydroxydopamine directly into the striatum, nucleus accumbens or the substantia nigra. In mice, lesions are made by administration of two injections at 16 hours interval, of 50 mg MPTP/Kg subcutaneously in volume of 0.5 ml of 0.9% saline solution. A subset of animals are allowed to survive one to eight days after lesioning and are then sacrificed. The numbers of surviving dopaminergic cells are assayed by tyrosine hydroxylase (TH) immunocytochemistry and are compared with
control animals that are lesioned prior to sacrifice but which do not receive growth factor treatment. Another subset of animals that are allowed to survive for prolonged periods and are subjected to behavioral testing and compared with lesioned controls animals (no growth factor treatment) or normal animals that are the same age as the model animals.
Alzheimer's Disease Model
Female Wistar rats (180-200 g) are used for this model. The animals receive EGF infusion treatments as described in Example 2 for 9 days. After various time points (1 wk, 2 wk, 1 mo., 2 mos., 4 mos. and 8 mos.) after EGF treatment, animals are lesioned so as to model Alzheimer's Disease. A retractable wire knife (Scouten Knife) is used to partially lesion the fimbria-fornix pathway. Animals are killed at various time points after the lesion (from 1 day to 8 weeks), and the numbers of surviving cells are assayed by Nissel staining in the septum. Controls, lesioned and treated animals are compared. A subset of animals is allowed to survive for prolonged periods for behavioral studies and compared with control animals.
Huntington's Disease Model
Following pretreatment with administered growth factors as described in Example I, the method described Levivier et al (1995) Neurosci. 69(l):43-50 is used to induce quinolinic acid lesions in striatal tissue. The numbers of neurons in the striatum are compared between controls, lesioned and treated animals.
Claims
1. A method of preventing the decline of the constitutively proliferating neural progenitor cell population of mammalian neural tissue in an aging mammal comprising administering to a mammal an effective amount of one or more growth factors to induce multipotent neural stem cell proliferation and provide a protective effect on said constitutively proliferating neural progenitor cell population.
2. The method of claim 1 wherein said neural tissue is healthy.
3. The method of claim 1 wherein said one or more growth factors is selected from the group consisting of EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGF╬▒), proliferation-inducing ligands which bind to the EGF and FGF receptors, and combinations thereof.
4. The method of claim 1 wherein said one or more growth factors is administered to one or more ventricles of said mammal.
5. The method of claim 1 wherein said one or more growth factors is admimstered by genetically modifying cells of said mammalian neural tissue to produce said one or more growth factors.
6. A method of protecting a mammalian neural tissue against neurological trauma or insult comprising administering to said mammal an effective amount of one or more growth factors to induce multipotent neural stem cell proliferation and provide a protective effect on said neural tissue at a time prior to an anticipated neurological insult or trauma.
7. The method of claim 6 wherein administration of said growth factor to said mammal is completed at least one week prior to said neurological insult or trauma.
8. The method of claim 6 wherein said anticipated neurological insult or trauma is due to surgical procedures performed on said mammal's brain.
9. The method of claim 6 wherein said one or more growth factors is selected from the group consisting of EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGF╬▒), proliferation-inducing ligands which bind to the EGF and FGF receptors, and combinations thereof.
10. The method of claim 6 wherein said one or more growth factors is administered to one or more ventricles of said mammal.
11. A method of preventing or reducing the manifestations of a neurological disease or disorder in a mammal comprising administering to said mammal an effective amount of one or more growth factors to induce multipotent neural stem cell proliferation at a time prior to occurrence of said manifestations.
12. The method of claim 11 wherein prior to administration of said one or more growth factors to said mammal, said mammal is diagnosed with a precursor event to said manifestations of said neurological disease or disorder.
13. The method of claim 11 wherein said one or more growth factors is selected from the group consisting of EGF, amphiregulin, acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), transforming growth factor alpha (TGF╬▒), proliferation-inducing ligands which bind to the EGF and FGF receptors, and combinations thereof.
14. The method of claim 11 wherein said one or more growth factors is administered to one or more ventricles of said mammal.
15. The method of claim 11 wherein said one or more growth factors is administered by genetically modifying cells of said mammalian neural tissue to produce said one or more growth factors.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002266659A CA2266659A1 (en) | 1996-11-15 | 1997-11-14 | Pretreatment with growth factors to protect against cns damage |
EP97913033A EP0941109A1 (en) | 1996-11-15 | 1997-11-14 | Pretreatment with growth factors to protect against cns damage |
AU50433/98A AU5043398A (en) | 1996-11-15 | 1997-11-14 | Pretreatment with growth factors to protect against cns damage |
JP52302998A JP2001504123A (en) | 1996-11-15 | 1997-11-14 | Pre-treatment with growth factors to protect against CNS disorders |
NO992364A NO992364D0 (en) | 1996-11-15 | 1999-05-14 | Pre-treatment with growth factors to protect against CNS-delegation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3048596P | 1996-11-15 | 1996-11-15 | |
US60/030,485 | 1996-11-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998022127A1 WO1998022127A1 (en) | 1998-05-28 |
WO1998022127A9 true WO1998022127A9 (en) | 1998-09-11 |
Family
ID=21854421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1997/000859 WO1998022127A1 (en) | 1996-11-15 | 1997-11-14 | Pretreatment with growth factors to protect against cns damage |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0941109A1 (en) |
JP (1) | JP2001504123A (en) |
AU (1) | AU5043398A (en) |
CA (1) | CA2266659A1 (en) |
NO (1) | NO992364D0 (en) |
WO (1) | WO1998022127A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006060A1 (en) | 1997-08-04 | 1999-02-11 | The Regents Of The University Of California | Methods for treating neurological deficits |
US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
EP1176870B1 (en) | 1999-04-26 | 2007-06-13 | Applied Protein Sciences, LLC | Tgf-alpha polypeptides, functional fragments and methods of use therefor |
US20020099008A1 (en) | 1999-04-26 | 2002-07-25 | Daniel R. Twardzik | Method for stimulating hematopoiesis using tgf-alpha |
US6677307B2 (en) | 1999-08-19 | 2004-01-13 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US6815418B2 (en) | 1999-08-19 | 2004-11-09 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US20020193301A1 (en) | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
WO2003060085A2 (en) | 2002-01-14 | 2003-07-24 | The Board Of Trustees Of The University Of Illinois | Mammalian neural stem cells, compositions and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE230795T1 (en) * | 1993-11-09 | 2003-01-15 | Neurospheres Holdings Ltd | IN SITU MODIFICATION AND MANIPULATION OF CENTRAL NERVOUS SYSTEM STEM CELLS |
JPH10509592A (en) * | 1994-11-14 | 1998-09-22 | ニューロスフィアーズ ホウルディングス リミテッド | Neural stem cell proliferation regulation |
WO1997035605A1 (en) * | 1996-03-26 | 1997-10-02 | Neurospheres Holdings Ltd. | Manipulation of mitotically active cells of the hippocampal region of the brain |
-
1997
- 1997-11-14 AU AU50433/98A patent/AU5043398A/en not_active Abandoned
- 1997-11-14 JP JP52302998A patent/JP2001504123A/en active Pending
- 1997-11-14 CA CA002266659A patent/CA2266659A1/en not_active Abandoned
- 1997-11-14 WO PCT/CA1997/000859 patent/WO1998022127A1/en not_active Application Discontinuation
- 1997-11-14 EP EP97913033A patent/EP0941109A1/en not_active Withdrawn
-
1999
- 1999-05-14 NO NO992364A patent/NO992364D0/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8158578B2 (en) | Methods for treating neurological deficits | |
Timmer et al. | Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms | |
Cheng et al. | NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults | |
Knuckey et al. | Differential neuronal and astrocytic expression of transforming growth factor beta isoforms in rat hippocampus following transient forebrain ischemia | |
AU716811B2 (en) | Regulation of neural stem cell proliferation | |
CA2461176C (en) | Treatment of central nervous system disorders by use of pdgf or vegf | |
CA2175992C (en) | In situ modification and manipulation of stem cells of the central nervous system | |
US8673594B2 (en) | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis | |
Riva et al. | Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone treatment | |
Tuszynski et al. | Central infusions of brain-derived neurotrophic factor and neurotrophin-45, but not nerve growth factor and neurotrophin-3, prevent loss of the cholinergic phenotype in injured adult motor neurons | |
Kuzis et al. | Time course and age dependence of motor neuron death following facial nerve crush injury: role of fibroblast growth factor | |
WO1998022127A9 (en) | Pretreatment with growth factors to protect against cns damage | |
EP0941109A1 (en) | Pretreatment with growth factors to protect against cns damage | |
Funa et al. | Enhanced synthesis of platelet-derived growth factor following injury induced by 6-hydroxydopamine in rat brain | |
AU5393001A (en) | Pretreatment with growth factors to protect against CNS damage | |
US20010007657A1 (en) | Compositions and methods for manipulating glial progenitor cells and treating neurological deficits | |
Sukhov et al. | Evidence that perihypoglossal neurons involved in vestibular‐auditory and gaze control functions respond to nerve growth factor | |
Yata et al. | Survival and axonal regeneration of off-center retinal ganglion cells of adult cats are promoted with an anti-glaucoma drug, nipradilol, but not BDNF and CNTF | |
Lindholm | Models to study the role of neurotrophic factors in neurodegeneration | |
MXPA00001197A (en) | Methods for treating neurological deficits | |
Sieber | Selective neurotrophic support of ventral mesencephalic dopamine neurons by local type 1 astrocytes | |
CA2204630A1 (en) | Regulation of neural stem cell proliferation |